Proactive Investors - Run By Investors For Investors

OptiBiotix set for a strong 2019 as agreements convert into revenues

OptiBiotix Health PLC's (LON:OPTI) Stephen O'Hara looks back on 2018 following the release of their full year results

Among some of the highlights in the period was a five-year deal with Akums Drugs and Pharmaceuticals to exclusively manufacture and supply supplements and drug products containing OptiBiotix’s LPLDL bacteria strain in India.

It also has an exclusive agreement with a US company for the LPLDL that carries six-figure milestone payments.

O'Hara says the raft of agreements signed are now starting to convert to revenues because of the lag period between signing and the start of cash coming in.

 
Meet Clinigen Group PLC, MaxCyte, Cello Health PLC, Oncimmune and Silence Therapeutics PLC at our event, London , 11 July 2019. Register here »
View full OPTI profile View Profile

OptiBiotix Health PLC Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use